Quince Therapeutics: Strategic Restart Focuses on Rare Lung Diseases for Investors
Reading Time: 3 minutes
The acquisition of Orphai Therapeutics signifies a shift towards rare lung diseases and opens new market opportunities. A price target of $77 by Citizens underscores confidence in the development pipeline and the advanced LAM-001 program. A completed financing round secures clinical research up to the expected study data in 2028. Strategic Shift Towards Rare Lung Diseases Quince Therapeutics (QNCX) positions itself after a fundamental realignment of its business model towards rare pulmonary diseases. The biopharmaceutical company addresses...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
